Table 4.
List of nanomaterials driven combinatorial immunotherapies for the treatment of cancer.
| Combinatorial agent / Carrier | Immunotherapy agent | Cancer Model |
|---|---|---|
| Chemo-immunotherapy | ||
| DOX / Thermoresponsive NPs, Lipoprotein nanodisc, Poly(amidoamine) dendrimer, Mesoporous silica NPs, Poly(lactic-co-glycolic) acid NPs | IFNγ, anti-PD-1Ab, CpG, ATRA, IL-2 CpG, anti-CLA4 Ab, anti-OX40 Ab |
B16F10, CT26, 22RV1, B16 melanoma, EL4, A20 lymphomas |
| PTX / poly(glycolic acid) NPs, Poly(lactic-co-glycolic) acid NPs; IL-10 siRNA / Poly(lactic-co-glycolic) acid NPs, RBC coated chitosan nanogel | Imiquimod, LPS, CpG, IL-2 | B16F10 |
| Cisplatin / Liposomes | CpG | B16F10 |
| Photothermal-Immunotherapy | ||
| Copper sulfide, gold NPs, CNT, ICG, IR7, melanin | CpG, GC, GM-CSF, OVA | 4T1, EMT6, B16, CT26, EG-7OVA |
| Polydopamine coated spiky gold NPs | DOX | CT26 |
| SWCNT, ICG, Bremaclilorin, Ce6 | Anti-CTLA-4 Ab, R837, SLPs, OVA, CpG | 4T1, CT26, TCI RMAEG7-OVA |
| Gold nanostar, Pyrolipid, IR700, TBP | Anti-PD-L1 Ab | MB49, MC38, CT26, 4T1 |
| Gold nanoshell | Adoptive T cells | B16F10 |
| Temoporfin, Ce6 | Anti-GR1 Ab, Anti-CD25 Ab, LCL521 | SCCVII, B16F10, |
| PPa | PD-L1 gene silencing | B16F10 |
| Photodynamic-Immunotherapy | ||
| NCP-pyrolipid | Oxaliplatin + anti-PD-L1 Ab | CT26, MC38 |
| ZnP-pyrolipid | Anti-PD-L1 Ab | 4T1 and TUBO |
| MOF, PpIX, H4TBC | IDO inhibitor, 1MT | CT26, MC38 |
| UCNPs-Ce6 | Imiqimod + anti-CTLA-4 Ab | CT26 |
| Radio-immunotherapy | ||
| Gold NPs | Anti-CD40 Ab | |
| Hf NPs | IDO inhibitor | |
| Gene-Immunotherapy | ||
| STAT3, IDO, SOCS1 siRNA / Liposome | ||
| SOCS1 siRNA, STAT3 siRNA, IL-10 siRNA/ PLGA NPs | imiquimod, OVA, | EG7-OVA, B cell lymphoma model |
| TGFβ siRNA/Liposomes | CpG, (TRP2) peptide | B16F10 |
Abbreviation: Doxorubicin (DOX), paclitaxel (PTX), all-trans-retinoic acid (ATRA), lipopolysaccharide (LPS), carbon nanotubes (CNT), 5,10,15,20-tetra(p-benzoato)porphyrin (TBP), Pyropheophorbide-a (PPa), 5,10,15,20-tetra(p-benzoato)chlorin (H4TBC)